Navigation Links
Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
Date:5/17/2011

ATLANTA, May 17, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election Dr. Steven C. Gilman to the Board of Directors of Inhibikase Therapeutics, Inc.

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

Dr. Steven Gilman joined Cubist Pharmaceuticals in 2008 and currently serves as the Cubist's Executive Vice President, Research & Development and Chief Scientific Officer. Before joining Cubist Pharmaceuticals, Dr. Gilman held several positions with ActivBiotics, Inc., including Chairman of the board of directors and President and CEO. Previously Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Additionally, Dr. Gilman served as Group Director at Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas.

Dr. Gilman currently serves on the Boards of Directors of the Massachusetts Biotechnology Association and the Massachusetts Society for Medical Research. In addition, Dr. Gilman serves on the Science and Regulatory Executive Committee of PhRMA. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.

Dr. Gilman joins Board members Dr. Stephen Fesik, Orrin H. Ingram, II Chair in Cancer Research at Vanderbilt University and former Vice-President for Cancer Research, Abbott Laboratories, Mr. David Gryska, former CFO of Celgene and Ms. Lisa Evren, Vice-President and Treasurer, Talisman-Energy.

"We are fortunate to add Dr. Gilman to the slate of new Board members elected in the last eight months.  Dr. Gilman's breadth of experience in pharmaceutical development and senior leadership will acceler
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
3. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
4. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
7. Echo Therapeutics Expands Into New Headquarters in Philadelphia
8. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
9. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
10. Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or ... developing, manufacturing, and acquiring cutting-edge technology, products and services ... be exhibiting at booth # 709 at the ... taking place on March 11-13, 2015 at Caesars Palace ... The 36 th annual NAPNAP Conference ...
(Date:3/5/2015)... 2015  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, today announced the appointment of ... The panel of experts will provide support for ... advance the company pipeline of novel investigational therapies ... a range of areas including opioid receptors, addiction, ...
(Date:3/5/2015)... 2015 LUNGevity Foundation, the nation,s leading ... Administration,s (FDA) approval of Bristol Myers Squibb,s new ... treatments add another critical new treatment option to ... a patient,s own immune system to fight cancerous ... for patients with squamous cell lung cancer, a ...
Breaking Medicine Technology:Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3
... 2011 The Food and Drug Administration (FDA) has recently ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) birth ... Avandia and other diabetes medicines that carry new restrictions ... recalled blood thinner These and other ...
... MINNEAPOLIS, June 28, 2011 Lutonix today announced ... begin enrollment in its LEVANT 2 IDE clinical trial for ... of CE Mark for its drug-coated balloon and ISO certification. ... FDA to initiate a drug-coated balloon trial.   ...
Cached Medicine Technology:Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team 2Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team 3
(Date:3/5/2015)... 2015 Rhode Island Medical Imaging (RIMI) was ... row to support the Providence College (PC) women’s basketball program’s ... purchase of the ‘Think Pink’ uniforms, which were worn during ... opponent DePaul University at Alumni Hall/Mullaney Gymnasium in Providence, R.I. ... of the PC women’s basketball’s ‘Pink Out’ event,” said Dr. ...
(Date:3/5/2015)... 05, 2015 On March 2, 2015, ... Labiaplasty on the Rise, Plastic Surgeons Say,” that comments ... Society for Aesthetic Plastic Surgery and the ... reported a year-over-year doubling of surgical butt augmentations performed ... in the article, this increase can be attributed to ...
(Date:3/5/2015)... TCS Healthcare Technologies (TCS), a leading provider ... management arena, is pleased to announce a webinar focusing ... Care™ (ACUITY) version 7.20. The session will focus on ... of automation. , The webinar, scheduled for March 18, ... Jeff Frater, RN, BSN, Director of Partner Development at ...
(Date:3/5/2015)... Calif. (PRWEB) March 05, 2015 ... beverages, today announced at Natural Products Expo West that ... are now 100 percent soy and dairy free. Califia ... single serve bottle and are packed with six grams ... protein that includes fiber, B vitamins and magnesium. , ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Taking ... in Fort Worth, Texas April 9-11th is IDRevolution ... company providing personalized nutrition. IDLife offers a ... IDNutrition. This customized approach to vitamin supplementation ... begins with a free HIPAA compliant online assessment ...
Breaking Medicine News(10 mins):Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2
... 50,000 Americans are diagnosed each year with ... surgery is usually not a viable,treatment option. ... an ongoing research endeavor. In an article ... of the National Cancer Institute, RTOG,researchers report ...
... sectors invested $140.5 billion in 2010 on research to ... and disability, according to Research!America,s latest annual estimate, available ... for only 5.5% of the $2.6 trillion the U.S. ... a percentage of health care spending has hovered around ...
... -- Two doses of the human papillomavirus (HPV) vaccine ... the three-dose regimen now being used, new U.S. government research ... from the National Cancer Institute,s Costa Rica Vaccine Trial, in ... from the Journal of the National Cancer Institute, ...
... released a report, "Improving Health in the United States: ... states that "good health is determined by more than ... growing body of research indicates that living conditionsincluding such ... to healthy and affordable foods and safe places to ...
... -- New X-rays revealed the best and most accurate images of ... The images of the fossil of an ancient species, ... on the evolution of the human brain, the study authors explained ... . The well-preserved MH 1 fossil was discovered by Lee ...
... multiple campuses of the University of California and a ... each to commercialize their ideas for new, lower cost ... for more affordable and efficient chronic disease management and ... grant program is led by the von Liebig Entrepreneurism ...
Cached Medicine News:Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2Health News:New report: US investment in health research remains stagnant 2Health News:Two Doses of HPV Vaccine May Work as Well as Three 2Health News:Health Impact Project director comments on new National Research Council report 2Health News:Accessible and affordable care at heart of health-care technology grants 2Health News:Accessible and affordable care at heart of health-care technology grants 3Health News:Accessible and affordable care at heart of health-care technology grants 4Health News:Accessible and affordable care at heart of health-care technology grants 5Health News:Accessible and affordable care at heart of health-care technology grants 6Health News:Accessible and affordable care at heart of health-care technology grants 7
... temporary internal drainage from the ureteropelvic junction ... engineered for ease of placement and patient ... designed for repositioning and ease of removal. ... polymer that when activated, attracts and holds ...
... The Panbio West Nile Virus IgM ... detection of IgM antibodies to West Nile ... the clinical laboratory diagnosis of West Nile ... consistent with encephalitis / meningitis. Positive results ...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: